Logo of iaiPermissionsJournals.ASM.orgJournalIAI ArticleJournal InfoAuthorsReviewers
Infect Immun. 1996 Mar; 64(3): 825–828.
PMCID: PMC173843

Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion.


Septic shock results from excessive stimulation of host immune cells, particularly monocytes and macrophages, by lipopolysaccharide (LPS) released from gram-negative bacteria. Macrophage-derived cytokines, such as tumor necrosis factor alpha (TNF-alpha) and interleukin-1beta (IL-1 beta), have been identified as central mediators in the pathogenesis of septic shock and the resultant mortality. Therefore, these cytokines were targets for experimental therapy for septic shock. Because of tetracycline's ability to intervene in cellular mechanisms involved in cytokine secretion, we tested the effect of tetracycline on LPS-induced septic shock and inflammatory lesions in mice. Tetracycline was found to protect mice against LPS-induced lethality and to abolish clinical signs of LPS-induced inflammatory lesions. This protection correlates with tetracycline's ability to reduce LPS-induced TNF-alpha levels in serum. Furthermore, tetracycline was found to inhibit LPS-induced TNF-alpha and IL-1 beta secretion, but not cytokine mRNA accumulation, in human monocytes in vitro. The results presented here suggest that tetracycline is a potent drug for LPS-induced pathology and that its mechanism of action involves blockage of posttranscriptional events of cytokine production.

Full Text

The Full Text of this article is available as a PDF (238K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10535–10539. [PMC free article] [PubMed]
  • Bauss F, Dröge W, Männel DN. Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun. 1987 Jul;55(7):1622–1625. [PMC free article] [PubMed]
  • Bernard GR. Sepsis trials. Intersection of investigation, regulation, funding, and practice. Am J Respir Crit Care Med. 1995 Jul;152(1):4–10. [PubMed]
  • Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 Aug 30;229(4716):869–871. [PubMed]
  • Bodmer M, Fournel MA, Hinshaw LB. Preclinical review of anti-tumor necrosis factor monoclonal antibodies. Crit Care Med. 1993 Oct;21(10 Suppl):S441–S446. [PubMed]
  • Bone RC. Gram-negative sepsis. Background, clinical features, and intervention. Chest. 1991 Sep;100(3):802–808. [PubMed]
  • Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991 Sep 15;115(6):457–469. [PubMed]
  • Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990 May;161(5):982–987. [PubMed]
  • Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, Hinshaw L, Taylor FB., Jr Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock. 1991 Feb;33(2):84–91. [PubMed]
  • Debets JM, Kampmeijer R, van der Linden MP, Buurman WA, van der Linden CJ. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med. 1989 Jun;17(6):489–494. [PubMed]
  • Dong Z, O'Brian CA, Fidler IJ. Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein-tyrosine kinase activity. J Leukoc Biol. 1993 Jan;53(1):53–60. [PubMed]
  • Dong Z, Qi X, Fidler IJ. Tyrosine phosphorylation of mitogen-activated protein kinases is necessary for activation of murine macrophages by natural and synthetic bacterial products. J Exp Med. 1993 Apr 1;177(4):1071–1077. [PMC free article] [PubMed]
  • Everaerdt B, Brouckaert P, Shaw A, Fiers W. Four different interleukin-1 species sensitize to the lethal action of tumour necrosis factor. Biochem Biophys Res Commun. 1989 Aug 30;163(1):378–385. [PubMed]
  • Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989 Nov 1;170(5):1627–1633. [PMC free article] [PubMed]
  • Gabler WL, Smith J, Tsukuda N. Comparison of doxycycline and a chemically modified tetracycline inhibition of leukocyte functions. Res Commun Chem Pathol Pharmacol. 1992 Nov;78(2):151–160. [PubMed]
  • Goldenthal EI. A compilation of LD50 values in newborn and adult animals. Toxicol Appl Pharmacol. 1971 Jan;18(1):185–207. [PubMed]
  • Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2(3):297–321. [PubMed]
  • Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, Lambert PH. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med. 1989 Jun 15;320(24):1586–1591. [PubMed]
  • Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, McNamara TF. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol. 1987 Feb;14(1):28–32. [PubMed]
  • Hesse DG, Tracey KJ, Fong Y, Manogue KR, Palladino MA, Jr, Cerami A, Shires GT, Lowry SF. Cytokine appearance in human endotoxemia and primate bacteremia. Surg Gynecol Obstet. 1988 Feb;166(2):147–153. [PubMed]
  • Hinshaw LB, Tekamp-Olson P, Chang AC, Lee PA, Taylor FB, Jr, Murray CK, Peer GT, Emerson TE, Jr, Passey RB, Kuo GC. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock. 1990 Mar;30(3):279–292. [PubMed]
  • Klosterhalfen B, Hörstmann-Jungemann K, Vogel P, Flohé S, Offner F, Kirkpatrick CJ, Heinrich PC. Time course of various inflammatory mediators during recurrent endotoxemia. Biochem Pharmacol. 1992 May 28;43(10):2103–2109. [PubMed]
  • Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet PF, Pointaire P, Vassalli P, Loetscher H. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol. 1991 Nov;21(11):2883–2886. [PubMed]
  • Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan;141(1):94–97. [PubMed]
  • Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology. 1993 Apr;187(3-5):403–416. [PubMed]
  • Martich GD, Danner RL, Ceska M, Suffredini AF. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med. 1991 Apr 1;173(4):1021–1024. [PMC free article] [PubMed]
  • Mayoral JL, Schweich CJ, Dunn DL. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis. Arch Surg. 1990 Jan;125(1):24–28. [PubMed]
  • Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 Jun 9;318(23):1481–1486. [PubMed]
  • Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, Torrance DS, Otten-Evans C, Greenstreet T, Weerawarna K, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994 Jul 21;370(6486):218–220. [PubMed]
  • Mózes T, Ben-Efraim S, Tak CJ, Heiligers JP, Saxena PR, Bonta IL. Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock. Immunol Lett. 1991 Feb;27(2):157–162. [PubMed]
  • Offner F, Philippé J, Vogelaers D, Colardyn F, Baele G, Baudrihaye M, Vermeulen A, Leroux-Roels G. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med. 1990 Jul;116(1):100–105. [PubMed]
  • Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988 Apr;81(4):1162–1172. [PMC free article] [PubMed]
  • Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993 May 20;328(20):1471–1477. [PubMed]
  • Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Krönke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993 May 7;73(3):457–467. [PubMed]
  • Raetz CR. Biochemistry of endotoxins. Annu Rev Biochem. 1990;59:129–170. [PubMed]
  • Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, Nathan CF. Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J. 1991 Sep;5(12):2652–2660. [PubMed]
  • Redl H, Schlag G, Ceska M, Davies J, Buurman WA. Interleukin-8 release in baboon septicemia is partially dependent on tumor necrosis factor. J Infect Dis. 1993 Jun;167(6):1464–1466. [PubMed]
  • Reimann T, Büscher D, Hipskind RA, Krautwald S, Lohmann-Matthes ML, Baccarini M. Lipopolysaccharide induces activation of the Raf-1/MAP kinase pathway. A putative role for Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes. J Immunol. 1994 Dec 15;153(12):5740–5749. [PubMed]
  • Remick DG, Strieter RM, Eskandari MK, Nguyen DT, Genord MA, Raiford CL, Kunkel SL. Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations. Am J Pathol. 1990 Jan;136(1):49–60. [PMC free article] [PubMed]
  • Rossomando EF, Kennedy JE, Hadjimichael J. Tumour necrosis factor alpha in gingival crevicular fluid as a possible indicator of periodontal disease in humans. Arch Oral Biol. 1990;35(6):431–434. [PubMed]
  • Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993 Aug 26;364(6440):798–802. [PubMed]
  • Shapira L, Takashiba S, Champagne C, Amar S, Van Dyke TE. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-alpha and IL-1 beta production by human monocytes. J Immunol. 1994 Aug 15;153(4):1818–1824. [PubMed]
  • Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone resorptive cytokines in periodontal disease. J Periodontol. 1991 Aug;62(8):504–509. [PubMed]
  • Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med. 1993 Oct;21(10 Suppl):S447–S463. [PubMed]
  • Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989 Aug 3;321(5):280–287. [PubMed]
  • Takashiba S, Van Dyke TE, Shapira L, Amar S. Lipopolysaccharide-inducible and salicylate-sensitive nuclear factor(s) on human tumor necrosis factor alpha promoter. Infect Immun. 1995 Apr;63(4):1529–1534. [PMC free article] [PubMed]
  • Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. [PubMed]
  • Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845–4849. [PMC free article] [PubMed]
  • Waage A, Espevik T. Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J Exp Med. 1988 Jun 1;167(6):1987–1992. [PMC free article] [PubMed]
  • Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. [PubMed]
  • Walsh CJ, Sugerman HJ, Mullen PG, Carey PD, Leeper-Woodford SK, Jesmok GJ, Ellis EF, Fowler AA. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg. 1992 Feb;127(2):138–145. [PubMed]
  • Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch Dermatol. 1994 Jun;130(6):748–752. [PubMed]
  • Weinstein SL, Gold MR, DeFranco AL. Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4148–4152. [PMC free article] [PubMed]
  • Weinstein SL, Sanghera JS, Lemke K, DeFranco AL, Pelech SL. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J Biol Chem. 1992 Jul 25;267(21):14955–14962. [PubMed]
  • Windsor AC, Mullen PG, Walsh CJ, Fisher BJ, Blocher CR, Jesmok G, Fowler AA, 3rd, Sugerman HJ. Delayed tumor necrosis factor alpha blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental gram-negative sepsis. Arch Surg. 1994 Jan;129(1):80–89. [PubMed]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...